These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31284119)

  • 1. Kratom as a substitute for opioids: Results from an online survey.
    Coe MA; Pillitteri JL; Sembower MA; Gerlach KK; Henningfield JE
    Drug Alcohol Depend; 2019 Sep; 202():24-32. PubMed ID: 31284119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Kratom use and health impact in the US-Results from an online survey.
    Grundmann O
    Drug Alcohol Depend; 2017 Jul; 176():63-70. PubMed ID: 28521200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.
    Smith KE; Rogers JM; Schriefer D; Grundmann O
    Drug Alcohol Depend; 2021 Sep; 226():108879. PubMed ID: 34216869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy.
    Faucher MA; Morillos S; Cordova P; McNeil-Santiel J; Onisko N; Adhikari EH; Nelson DB
    J Midwifery Womens Health; 2024; 69(1):144-149. PubMed ID: 37679866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic and clinical assessment of kratom: An update.
    White CM
    Am J Health Syst Pharm; 2019 Nov; 76(23):1915-1925. PubMed ID: 31626272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
    Henningfield JE; Fant RV; Wang DW
    Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Pharmacology and Legal Status of Kratom.
    Prozialeck WC
    J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder.
    Bowman J; Lai M; Charles JE; Gordon AJ; Smid MC
    J Addict Med; 2023 Nov-Dec 01; 17(6):722-724. PubMed ID: 37934544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of death associated with kratom use compared to opioids.
    Henningfield JE; Grundmann O; Babin JK; Fant RV; Wang DW; Cone EJ
    Prev Med; 2019 Nov; 128():105851. PubMed ID: 31647958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kratom: Substance of Abuse or Therapeutic Plant?
    Gorelick DA
    Psychiatr Clin North Am; 2022 Sep; 45(3):415-430. PubMed ID: 36055730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.